Reducing AIR Pollution Exposure to Lower Blood PRESSURE Among New York City Public Housing Residents

Blood Pressure Clinical Trial

— AirPressureNYC  

Official title:

Reducing AIR Pollution Exposure to Lower Blood PRESSURE Among New York City Public Housing Residents

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05874479
• Other study ID #: 23-00517
• Status: Recruiting
• Phase: N/A
• Start date: December 20, 2023
• Est. completion date: March 2028

Study information

• Verified date: December 2023
• Source: NYU Langone Health
• Contact: Jonathan Newman
• Phone: (212) 263-9393
• Email: AirPressureNYC[@]nyulangone.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Fine particulate matter <2.5 µm (PM2.5) air pollution is the fifth leading risk factor for global mortality, with the largest portion of deaths due to cardiovascular disease (CVD). While several mechanisms are responsible, PM2.5-induced elevations in blood pressure (BP) may be relevant. Indoor portable air cleaners (PACs) are a novel approach to reduce exposure to PM2.5 and potentially lower blood pressure. The current study is being conducted to provide evidence that PACs reduce PM2.5 exposure and lower systolic blood pressure (SBP) in key patient populations.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 440
• Est. completion date: March 2028
• Est. primary completion date: September 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• self-reported nonsmokers living in a nonsmoking household.
• adults living with hypertension (HTN) from NYC public housing.

Exclusion Criteria:

• History of major known arrhythmias (e.g. atrial flutter or fibrillation, ventricular tachycardia).
• Screening systolic BP =160 mm Hg or diastolic BP =100 mm Hg (i.e. severe hypertension by the 2017 ACC/AHA BP guideline).
• A change in drug regimen in the prior 2 weeks or a planned change in drug regimen during the first 30 days for those taking antihypertensive medication.
• Current smoking or living with an active smoker who smokes indoors
• Planned travel out of NYC for =2 weeks in next 6 months
• Incarcerated
• Pregnant
• Unable/unwilling to consent
• Established cardiovascular disease
• End-stage renal disease (chronic kidney disease stage IV or on dialysis)
• Barrier to technology use (e.g., visual or hearing impairment)
• Lung disease requiring oxygen
• Cancer receiving treatment

Related Conditions & MeSH terms

• Blood Pressure
• Hypotension

Intervention

Device:
• Active PAC
The active PAC will contain HEPA filters inside the device.
• Sham PAC
The sham PAC will contain no HEPA filters inside the device.

Locations

Country	Name	City	State
United States	NYU Langone Health	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
NYU Langone Health	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Average Self-Measured Morning Home Systolic Blood Pressure (AM H-SBP) over 30 Days	Participants measure HBP every day between 6-9 am.	Up to Day 30
Secondary	Average Self-Measured Morning Home Systolic Blood Pressure (AM H-SBP) over 90 Days	Participants measure HBP every day between 6-9 am.	Up to Day 90
Secondary	Average Self-Measured Morning Home Systolic Blood Pressure (AM H-SBP) over 180 Days	Participants measure HBP every day between 6-9 am.	Up to Day 180